Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

NCT07276386 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG: Melphalan/HDS (Percutaneous Hepatic Perfusion)
DRUG: Tebentafusp

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]